Zhou, Jia http://orcid.org/0000-0002-2156-0483
Gelot, Camille
Pantelidou, Constantia http://orcid.org/0000-0003-2750-9352
Li, Adam
Yücel, Hatice
Davis, Rachel E.
Färkkilä, Anniina http://orcid.org/0000-0002-3558-6617
Kochupurakkal, Bose
Syed, Aleem
Shapiro, Geoffrey I.
Tainer, John A.
Blagg, Brian S. J.
Ceccaldi, Raphael http://orcid.org/0000-0003-3049-4278
D’Andrea, Alan D. http://orcid.org/0000-0001-6168-6294
Article History
Received: 30 September 2020
Accepted: 24 March 2021
First Online: 17 June 2021
Competing interests
: A.D.D. reports receiving commercial research grants from Eli Lilly and Company, Sierra Oncology and EMD Serono and is a consultant and/or advisory board member for Eli Lilly and Company, Sierra Oncology, Cedilla, Ideaya, Cyteir and EMD Serono. G.I.S. has received research funding from Eli Lilly, Merck KGaA/EMD Serono, Merck and Sierra Oncology, and he has served on advisory boards for Pfizer, Eli Lilly, G1 Therapeutics, Roche, Merck KGaA/EMD Serono, Sierra Oncology, Bicycle Therapeutics, Artios, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Boehringer Ingelheim, ImmunoMet and Asana. The remaining authors declare no competing interests.